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ORIGINAL ARTICLE
Clostridium difficile infection in patients with inflammatory bowel disease:
a case control study
Krista Vitikainena, Johanna Haapam€akia, Martti F€arkkil€aa , Veli-Jukka Anttilab and Perttu Arkkilaa
aDepartment of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland; bDepartment of Infectious Diseases,
Helsinki University Central Hospital, Helsinki, Finland
ABSTRACT
Objective: Characterization of predisposing factors for Clostridium difficile infection recurrence (rCDI)
and outcome in inflammatory bowel disease (IBD) patients.
Methods: Clinical characteristics of 167 inflammatory bowel disease patients with Clostridium difficile
infection (IBD-CDI cohort) treated in Helsinki University Central Hospital were gathered. Medical history
of the last three months preceding a toxin positive CDI test was recorded. Parameters, including ribo-
type of C. difficile, mortality and recurrence were compared with age and gender-matched C. difficile
patients (CDI cohort).
Results: No difference was found in rCDI between IBD-CDI and CDI cohorts. As compared with IBD
subtypes, rCDI was least common among patients with Crohn’s disease. The use of immunosuppres-
sant therapy was higher in IBD patients with two or more CDI episodes. C. difficile ribotype 027
increased the rates for rCDI in IBD patients but not in non-IBD-CDI patients. The prevalence of 027
ribotype and mortality rates did not differ significantly among the cohorts. None of the IBD patients
underwent colectomy upon CDI.
Conclusion: IBD patients are not more susceptible for rCDI than non-IBD patients. Predisposing factors
for rCDI among IBD patients are associated with immunosuppressant treatments, colon affecting IBD
and CDI caused by ribotype 027. CDI does not worsen the prognosis of IBD patients.
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Introduction
Clostridium difficile infection (CDI) is the most common cause of
antibiotic-associated diarrhea, especially among hospitalized
patients. Clinical manifestations of CDI range from asymptom-
atic carriage to severe fulminant colitis and death. Dismal prog-
nosis is associated especially with a hypervirulent strain of C.
difficile (NAP1/B1/027). The 027-ribotype of C. difficile is charac-
terized by increased disease acitivty and transmissibility [1].
CDI is classically considered a nosocomial concern but the
prevalence of infection in community has increased world-
wide, especially in certain patient groups. Patients with
inflammatory bowel disease (IBD) are one of the patient
groups among the incidence of CDI has increased over the
past few decades, especially in the industrialized countries
[2,3]. IBD patients have shown to be more susceptible to
develop CDI with more severe outcomes, such as colecto-
mies and mortality, than non-IBD-CDI patients [4,5]. In add-
ition to disease susceptibility, IBD patients are documented
to have 33% higher risk to develop recurrence of CDI com-
pared with non-IBD patients with CDI [6].
Currently, the predisposing factors for CDI in IBD patients
have been studied widely in recent studies, while risk factors
for rCDI remain poorly established. Conventional risk factors
for CDI in the general population include advanced age,
chemotherapy, co-morbidities, prolonged hospitalization and
use of certain drugs, most notably antibiotics and proton
pump inhibitors (PPIs) [7–9]. In IBD, both Crohn’s disease
(CD) and ulcerative colitis (UC) patients are at high-risk for
CDI, although patients with UC have been reported to be
more susceptible to CDI than CD patients [10–12]. IBD-associ-
ated treatment factors, such as use of immunosuppressants,
have also been suggested to increase the risk for CDI.
Compared with other immunosuppressive agents, use of cor-
ticosteroids has shown a threefold increase in the rates of
CDI in IBD patients [13,14]. Antibiotics in turn, do not seem
to play a critical role in triggering CDI in these patients [15].
Factors that increase the risk for rCDI in IBD patients are
related with 5-aminosalicylic acid (5-ASA), steroids, antibiot-
ics, biologic therapy and IBD that affects colon [6]. To our
knowledge, the prevalence of C. difficile BI/NAPI/027 ribotype
and its effect on recurrent infections in IBD patients have
not been investigated previously.
This is a comprehensive regional study of IBD-CDI and
CDI patients in the southern of Finland. Our study focused
on the differences between clinical characteristics of IBD and
CDI patients. We compared IBD patients with CDI to CDI
patients without IBD to determine predisposing factors to
rCDI. We analyzed IBD-CDI and CDI patients’ prognosis in
general in a vast study cohort while many previous studies
have processed prognosis more concisely with smaller study
cohorts or only by the risk of colectomy [4].
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Material and methods
In this retrospective cohort study, 167 IBD patients with CDI
were enrolled from medical records of Helsinki University
Hospital (HUH) register. The medical records are from 2008
to 2013. The data from records were collected between
June and July in 2016. Following variant forms of IBD were
included in our study: UC (n¼ 105, 62.9%), CD (n¼ 48,
28.7%) and unspecified IBD (IBD-U/indeterminate colitis,
n¼ 14, 8.4%). Diagnosis of IBD was done according to
standard clinical, endoscopic, radiological and histologic
criteria. The study was approved by the institutional review
board of Helsinki University Hospital.
Clinical parameters including CDI episodes and exposure
to commonly used medications were collected from IBD-
CDI patients’ medical records. Usage of IBD-related drugs,
antibiotics, NSAIDs and PPIs during the last three months
before a toxin positive CDI test were recorded. No exclusion
criteria were used in the study and possible comorbidities
in either of the cohorts were ignored. For mortality ana-
lyzes, death for any cause within 30 days after established
CDI diagnosis was recorded.
In Southern Finland, three step diagnostic methods for
detection of CDI are used since the year of 2008: C. difficile
cytotoxin assay and stool culture to isolate C. difficile with
subsequent cytotoxin assay, if direct cytotoxin assay was
negative; and if the culture was positive, 027 was tested by
the multiplex PCR method published elsewhere [16]. These
tests are performed for IBD patients, who are symptomatic
after antibiotics and for patients with IBD exacerbation.
Recurrence of CDI is defined as recurrent of diarrhea with
a positive stool test at least 14 days after the initial episode
of symptomatic CDI.
Age- and gender-matched control group including non-
IBD-related CDI patients (CDI cohort) was gathered from
HUH register to compare the characteristics of patients in
IBD-CDI cohort.
Statistical methods
Patient characteristics between groups were analyzed using
the chi-square test, the Fisher exact test and the Bonferroni
multiple comparison test. One-way analysis of variance was
used for continuous variables. A p value of <.05 was consid-
ered statistically significant. All calculations were accom-
plished with NCSS-2000 software (Kaysville, UT, USA).
Results
Patient characteristics
A total of 167 IBD patients with CDI were included in our
IBD-related CDI (IBD-CDI) study cohort with variable number
of CDI episodes. Patient characteristics of both cohorts are
represented in Table 1. The mean age in IBD-CDI cohort was
46.1 (range 6.4–91.9 years).
Recurrence of CDI
The overall count of CDI episodes is shown in Table 1.
The number of recurrences in rCDI was between two to five
(meanþ/–SD 1.54þ/–0,97) and two to seven (meanþ/–SD
1.52þ/–1,08) episodes in the IBD-CDI and CDI cohort,
respectively.
No significant difference in recurrence rate was evident
between IBD-CDI and CDI cohorts (p¼ .551). A total of 128
(IBD-CDI) and 126 (CDI) episodes occurred among men
(p¼ .663), 129 (IBD-CDI) and 123 (CDI) among females
(p¼ .216). Within the IBD-CDI cohort alone rCDI seemed to
occur more frequently among females than among men,
although statistical significance was not found. Comparing
rCDI between IBD subtypes, the recurrence of CDI was most
infrequent in patients with CD (Figure 1). CDI episodes (%) in
non-IBD-CDI cohort are shown in Figure 2.
Table 1. Characteristics of the patients.
IBD-CDI
n¼ 167
CDI without
IBD n¼ 164
Age (Average ± SD) yrs 46.1 ± 21.0 42.9 ± 20.2
Gender Males n (%) 85 (50.9) 83 (50.6)
Females n (%) 82 (49.1) 81 (49.4)
IBD subtypes CD n (%) 48 (28.7) NA
UC n (%) 105 (62.9) NA
IBD-U n (%) 14 (8.4) NA
CDI episodes One (%) 116 (69.5) 120 (73.2)
Two (%) 26 (15.6) 23 (14.0)
Three or more (%) 25 (15.0) 21 (12.8)
Ribotype 027 (%) 4 (2.4) 11 (6.7)
Other (%) 160 (95.8) 149 (90.9)
NA (%) 3 (1.8)
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Figure 1. Clostridium difficile episodes (%) in variant forms of IBD patients.
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Figure 2. Clostridium difficile episodes (%) in non-IBD-CDI patients.
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Drug usage in the IBD-CDI cohort was recorded for three
months preceding CDI episode for available cases (Table 2).
Corticosteroids and 5-ASA were the most commonly used
medication in the IBD-CDI cohort. Over half of the patients
had been exposed to 5-ASA or systemic corticosteroid and a
few to local corticosteroid before CDI episode. Proportionally
the usage of both systemic corticosteroid and 5-ASA was
higher in patients with two or more CDI episodes, although
statistical significance was not reached. Patients with no cor-
ticosteroid or 5-ASA-intake were not as susceptible to have a
recurrent infection. Other medications in our study did not
appear to have a similar impact on the rate of recurrence of
CDI within the IBD-CDI cohort.
Patients in IBD-CDI cohort had also frequently received
antibiotic therapy during the previous three months before a
CDI episode: 73.4% of all IBD-CDI patients were exposed to
antibiotics (34/40 of CD patients, 73/105 of UC patients and
9/13 of IBD-U patients, unknown from 9 IBD-CDI patients).
Especially the use of broad spectrum antibiotics seemed to
be common in IBD patients before the CDI diagnosis. No sig-
nificant difference was found in different antibiotics and dif-
ferent IBD types.
C. difficile strains
To examine differences in C. difficile ribotypes between IBD
and non-IBD-related CDI patients, we evaluated the preva-
lence of 027 ribotype between these cohorts. Ribotype 027
represented a minority of CDI in both the cohorts with a
slightly higher prevalence in non-IBD-related CDI cases, but
no statistical significant difference was found (p¼ .101). We
also compared the effect of C. difficile ribotype 027 to recur-
rent infections in both the cohorts. The risk for rCDI was
higher in IBD patients with CDI caused by ribotype 027 as
compared with non-IBD-CDI patients. In IBD cohort CDI epi-
sodes according to ribotype 027 status were as follows: 1/
116 non-recurrent CDI caused by ribotype 027 vs. 3/48 recur-
rent infection caused by ribotype 027, 115/116 non-recurrent
CDI caused by other ribotype than 027 vs. 45/48 recurrent
CDI caused by other ribotype than 027 (p¼ .041).
Prognosis
We wanted to clarify the effect of CDI on IBD patients’ mor-
tality. When comparing the rates of 30-day mortality after
CDI episode between genders in the IBD-CDI and CDI
cohorts, we identified a difference in CDI-related mortality
among men: 1.2% of IBD-CDI and 7.4% of CDI patients suc-
cumbed during 30 days after CDI diagnosis (p¼ .046).
Mortality rates did not differ among females (IBD-CDI vs. CDI
patients, 2.4% vs. 2.5%, p¼ .970).
In general, IBD-CDI patients also had lower mortality rates
compared to CDI patients. Two-day mortality rates were
none vs. 1 (0.6%) in IBD-CDI and CDI patients, seven-day
mortality rates 1 (0.6%) vs. 4 (2.5%) and 30-day mortality
rates 3 (1.8%) vs. 8 (5.0%), respectively. Altogether, short-
term survival (30 days post-infection) after CDI episode was
98.2% in IBD-related CDI and 95.0% in non-IBD-related
CDI (p¼ .108).
We also wanted to evaluate IBD-CDI patients’ risk to
undergo colectomy. In our study, none of the IBD patients
underwent surgery after CDI.
Discussion
IBD Patients are at increased risk for developing symptomatic
CDI with worse clinical outcomes as compared with the gen-
eral population. IBD patients are also more susceptible to
have recurrences of CDI. Predisposing factors for CDI in IBD
patients have been widely covered in recent studies, while
the risk for rCDI in IBD patients has not garnered much
attention. The present study evaluated which are the predis-
posing factors for rCDI in IBD patients. The most important
risk factor for rCDI seems to be the use of systemic cortico-
steroid. Moreover, higher 5-ASA-intake was associated with
two or more CDI episodes. However, the prevalence of rCDI,
027 ribotype and mortality is not higher in IBD-CDI com-
pared to non-IBD-CDI patients. None of the IBD patients
underwent colectomy after CDI. CDI caused by ribotype 027
increases the risk for rCDI in IBD patients.
The incidence of CDI has been increasing during the
twenty-first century. It is the most common cause of anti-
biotic-associated diarrhea, especially among the hospitalized.
CDI is classically considered a nosocomial concern but the
incidence is also detected to be higher in non-hospitalized
patients with IBD [10,17]. The increased incidence of CDI is
also coupled with higher risk of recurrence among IBD
patients. CDI recurrences have been shown to occur 33%
more frequently among IBD patients as compared to non-
IBD-CDI patients [6]. In our study cohort, there was no differ-
ence in the rates of rCDI between IBD and non-IBD-related
CDI patients.
Differences in the rates of rCDI between IBD subtypes
have also been established [18,19]. UC and non-ileal CD
patients have been reported not only to have a higher
prevalence of CDI but also increased risk for recurrent infec-
tions [6,11]. Our study recorded least rCDI episodes in CD
patients. Recurrences of CDI were frequently seen in other
forms of IBD (UC and IBD-U). The greater prevalence of CDI
Table 2. CDI episodes in IBD patients using different treatments.
Once users %
(n/data obtained)
Twice users %
(n/data obtained)
Three or more
episodes users %
(n/data obtained)
5-ASA 65,8% (73/111) 73,1% (19/26) 75,0% (18/24)
Corticosteroids
Systemic 52,3% (57/109) 56,0% (14/25) 58,3% (14/24)
Local 5,5% (6/109) 8,0% (2/25) 8,3% (2/24)
Both 5,5% (6/109) 20,0% (5/25) 4,2% (1/24)
Thiopurines 36,4% (40/110) 38,5% (10/26) 29,2% (7/24)
Infliximab 12,7% (14/110) 11,5% (3/26) 4,2% (1/24)
Adalimumab 3,6% (4/110) 0/26 0/24
Vedolizumab 0/110 0/26 0/24
Antibiotics 75,0% (81/108) 68,0% (17/25) 75,0% (18/24)
NSAIDsa 28,2% (31/110) 15,4% (4/26) 25,0% (6/24)
PPIsb 47,3% (52/110) 53,8% (14/26) 45,8% (11/24)
aNonsteroidal anti-inflammatory drugs.
bProton pump inhibitors. No statistically significant differences were found.
Vedolizumab and adalimumab were not used in our cohort.
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and its recurrent infections may be due to the manifestation
of the disease which in these variant forms is limited to the
colon, where the C. difficile bacterium colonizes, in contrast
to CD which can affect any parts of the gastrointestinal tract.
Hypothetically, one would expect that a colon-manifesting
process could set up the premises for CDI colonization,
which could explain the greater prevalence of recurrent
infections in other forms of IBD.
Currently, predisposing pharmacological and disease asso-
ciated factors for rCDI in IBD patients are only poorly estab-
lished. Certain drugs such as corticosteroids, 5-ASA, biologics
and antibiotics have been associated with rCDI in a smaller
IBD cohort study [6].
Corticosteroids have been used as a conventional treat-
ment of IBD due to its effectiveness in a rapid resolution of
IBD symptoms. However, steroid usage has been shown to
increase a risk to develop rCDI in patients with concomitant
IBD [6]. Our study further highlights the impact of high cor-
ticosteroid-intake and incidence of rCDI in IBD patients. In
our IBD-CDI cohort as much as 61.4% of all patients had
used systemic corticosteroids during the previous three
months preceding a CDI. Moreover, the intake of corticoste-
roids was further enriched in patients with CDI recurrences.
However, since corticosteroids are conventionally given to
IBD patients with an IBD exacerbation, it is also possible that
the flare ups could have an effect on developing a recur-
rence infection independent of steroid exposure. For clini-
cians it can cause confusion whether to decrease or increase
the dose of immunosuppressant in IBD patients with CDI.
However, according to the latest research, when the diagno-
sis of CDI is confirmed, initiation of immunosuppressive
agents may be considered after 48–72 h when targeted anti-
biotics for CDI in IBD patients are given [20].
5-ASA has been used as an anti-inflammatory drug for
induction and maintenance of remission in IBD patients and
has also been associated with rCDI [6]. Many of IBD-CDI
patients in our study cohort had received 5-ASA preceding
CDI episode. Moreover, within IBD-CDI cohort 5-ASA usage
was more common among patients with two or more CDI
episodes. It has been hypothesized that the intake of 5-ASA
could develop dysbiosis which alone or co-operatively with
colon affecting IBD could make the patients more suscep-
tible to CDI and its recurrent episodes [21,22].
Antibiotics do not seem to play a critical role in triggering
CDI in IBD patients [10,15]. As compared to nosocomial CDI,
IBD-related infection appears to occur in younger patients
who have not received antibiotics recently. Antibiotic expos-
ure has found to occur only in 40–60% of IBD patients with
subsequent CDI [23,24]. However, in IBD patients antibiotics
have been associated with rCDI [6]. In our study cohort,
majority of the IBD patients (73.4%) were exposed to antibi-
otics in the past three months before CDI diagnosis. While
almost all antibiotics have been associated with CDI-related
diarrhea in general, the most common association has been
noticed to be with only certain antibiotics, including fluoro-
quinolones, which are commonly used in IBD [25]. Thus,
some of the same antibiotics which most often cause CDI-
related diarrhea are used as a treatment in IBD patients who
already have increased risk to develop CDI. This is an indica-
tion for careful consideration when to start antibiotics for
IBD patients.
The prevalence of C. difficile ribotype 027 has not been
thoroughly investigated among patients with IBD. In the
general population, the hypervirulent form of C. difficile has
been associated with more severe disease and dismal out-
come [1]. In our study, ribotype 027 represented minority of
CDI cases in both the cohorts and the prevalence did not
differ significantly between IBD-CDI ad CDI patients.
However, ribotype 027 seems to increase the risk for rCDI in
IBD patients.
Previous studies have been considering the effects of CDI
in IBD patient outcomes, such as in mortality and colectomy.
They have shown mortality rates to be twice higher in IBD
patients with CDI as compared to non-IBD patients with CDI
and even four-fold higher than in an inpatient with IBD
alone [11,26]. In our study, significant difference between
these two groups in general was not noticed. IBD-CDI
patients seem to have even less mortality compared to non-
IBD-CDI patients. This favorable mortality rate among IBD-
related cases may arise due to lack of traditional risk factors,
including other co-morbidities in comparison to non-IBD-
related CDI. In fact, IBD may often be the only underlying
disease in these CDI cases. Moreover, the risk of colectomy
was not either elevated in our IBD-CDI cohort, while none of
the IBD-CDI patient underwent colectomy upon infection.
Here, we have gathered and analyzed a retrospective
cohort of Finnish IBD patients with CDI and compared
patient characteristics, risk factors and CDI recurrence with
non-IBD-related CDI patients. Our study complements previ-
ous studies and provides a more insight into the poorly char-
acterized CDI recurrence, rate and prognosis among IBD
patients. The strength of our study is a large IBD-CDI cohort
and C. difficile ribotype 027 analyzation. The weakness of our
study was ignorance of disease activity in the IBD-CDI cohort.
At the moment, diagnosis of CDI in IBD patients may be diffi-
cult due to overlapping clinical symptoms of CDI and IBD
flare up. Clinicians should accurately document each case
with rapid diagnosis and subsequent adequate therapy.
Routine stool sample screening for CDI in each case with
characteristics of IBD exacerbation or infectious colitis is rec-
ommended before giving any antibiotics.
Conclusions
According to our research, the most important risk factor for
rCDI was systemic corticosteroid usage. Moreover, higher 5-
ASA and corticosteroid-intake was associated with two or
more CDI episodes. We identified no significant difference in
the prevalence of rCDI, ribotype 027 and mortality between
IBD-CDI and CDI cohorts. CDI caused by ribotype 027
increases the risk for rCDI in IBD patients. CDI seems not to
increase the risk for colectomies in IBD patients after CDI epi-
sode. More prospective studies are required to evaluate
clearly different risk factors for CDI in IBD patients.
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